Experts Slam U.S. Response to Fatal Hantavirus Cruise Ship Outbreak

Infectious disease experts on May 7, 2026, criticized the response of U.S. Health officials to a hantavirus outbreak that resulted in three deaths among passengers aboard the cruise ship MV Hondius.

The outbreak involved the Andes virus, a specific strain of hantavirus endemic to South America. According to the World Health Organization, three people died and at least eight others became ill during the voyage.

The Infectious Diseases Society of America (IDSA) raised concerns regarding the coordination and speed of the public health response. During a press briefing on May 7, 2026, Jeanne M. Marrazzo, MD, MPH, the CEO of the IDSA, characterized the situation as a travesty.

I’m not overstating this, it is a travesty

Jeanne M. Marrazzo, MD, MPH, CEO of the Infectious Diseases Society of America

Among the passengers on the MV Hondius were 17 Americans. The presence of U.S. Citizens in the affected group has placed the response under the purview of U.S. Health agencies, including the Centers for Disease Control and Prevention (CDC).

The Andes virus is distinguished from most other hantaviruses by its mode of transmission. While most hantaviruses are zoonotic, meaning they are transmitted from infected rodents to humans through the inhalation of aerosolized virus particles in droppings or urine, the Andes virus can be transmitted from person to person.

The CDC notes that person-to-person transmission of the Andes virus typically occurs only through close contact. This characteristic increases the risk of outbreaks in confined environments, such as cruise ships, where passengers and crew live in proximity.

Clinical manifestation of hantaviruses often presents as Hantavirus Pulmonary Syndrome (HPS). This condition typically begins with flu-like symptoms, including fever, muscle aches, and fatigue, before progressing rapidly to severe respiratory distress and pulmonary edema.

Because the early symptoms of HPS are non-specific, diagnosis can be delayed, which often complicates treatment and increases mortality rates. There is currently no specific antiviral treatment or vaccine for the Andes virus, meaning care is primarily supportive, often requiring mechanical ventilation in intensive care units.

The criticism from the IDSA suggests a perceived failure in the monitoring or rapid containment strategies employed by health officials once the outbreak was identified on the vessel. The ability of the Andes virus to spread between humans makes rapid isolation and contact tracing critical to preventing further casualties.

Public health officials are now tasked with evaluating the timeline of the response and determining why the containment measures were deemed insufficient by the medical community.

The incident underscores the ongoing challenge of managing rare, high-mortality pathogens in the context of global travel. Experts emphasize that the potential for person-to-person transmission in the Andes strain requires a different surveillance protocol than that used for standard rodent-borne hantaviruses.